Results 151 to 160 of about 21,331 (238)

Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [PDF]

Int J Biol Sci
Saad AAA, Ge L, Wang H, Xia Y, Li J, Qiao S, Yi C, Wang X, Wang Z, Zhou D, Wang H.   +10 more
europepmc   +1 more source

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. [PDF]

J Clin Med, 2023
Guidetti F, Arribas AJ, Sartori G, Spriano F, Barnabei L, Tarantelli C, Von Roemeling R, Martinez E, Zucca E, Bertoni F.   +9 more
europepmc   +1 more source

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study. [PDF]

J Neurooncol
Chang X, He Z, Wang H, Zhu H, Guo Y, Zou D, Zhao Z, Song T, Hu R, Ni J, Zhao H, Hui W, Liu Z, Li Z, Zhang W, Zhou D, Zhang Y, Sun W.   +17 more
europepmc   +1 more source

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. [PDF]

ACS Pharmacol Transl Sci
Corrionero A, Zhang X, Alfonso P, Morris PJ, Klumpp-Thomas C, Melani C, McKnight C, Phelan JD, Holland D, Wilson K, Hoyt SB, Roschewski M, Tonge PJ, Wilson W, Ceribelli M, Staudt LM, Thomas CJ.   +16 more
europepmc   +1 more source

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors. [PDF]

Hemasphere, 2023
Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano CA, Campanile R, Scarfò L, Biedenweg D, Fregin B, Zamai M, Díaz Torres A, Labrador Cantarero V, Ghia P, Otto O, Mantegazza F, Caiolfa VR, Scielzo C.   +17 more
europepmc   +1 more source

BTK Inhibitor ICP-022 [PDF]

, 2020
openaire   +1 more source

Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]

Oncol Rev
Visentin A, Mauro FR.
europepmc   +1 more source

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. [PDF]

Drug Des Devel Ther, 2022
Carnero Contentti E, Correale J.
europepmc   +1 more source

Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report. [PDF]

AIDS Res Ther, 2023
Zhou Y, Wang X, Lin X, Wang J, Yan X, Wen Y.   +5 more
europepmc   +1 more source

Recent Progress of Irreversible BTK Inhibitors

Transactions on Materials, Biotechnology and Life Sciences
In recent years, Bruton tyrosine kinase (BTK) inhibitors that selectively inhibit B cell receptor (BCR) signaling have become a popular and effective treatment for lymphomas in the public. As the pivotal tyrosine kinase BTK regulates the BCR pathway, BTK inhibitors were developed to block the pathway by binding with BTK thereby relieving the B-cell ...
openaire   +1 more source